Indirect comparisons of brigatinib and alectinib for front-line ALK -positive non-small-cell lung cancer.
Karen L ReckampHuamao Mark LinHolly L CranmerYanyu WuPingkuan ZhangLaura J WaltonStephen KayAllie CichewiczBinod NeupaneKyle FahrbachSanjay PopatD Ross CamidgePublished in: Future oncology (London, England) (2022)
Aim: To conduct an indirect treatment comparison (ITC) of the relative efficacy of brigatinib and alectinib for progression-free survival in people with tyrosine kinase inhibitor (TKI)-naive ALK -positive non-small-cell lung cancer (NSCLC). Methods: Final aggregate and patient-level data from the ALTA-1L trial comparing brigatinib to crizotinib and published aggregate data from ALEX (comparing alectinib to crizotinib) were contrasted using Bucher ITC and matching-adjusted indirect comparisons (MAICs). Results: No statistically significant differences were identified between brigatinib and alectinib in reducing the risk of disease progression overall and in patients with baseline central nervous system metastases. Conclusion: Brigatinib appeared similar to alectinib in reducing risk of disease progression for people with TKI-naive ALK -positive NSCLC.
Keyphrases
- advanced non small cell lung cancer
- epidermal growth factor receptor
- free survival
- hiv infected
- big data
- small cell lung cancer
- tyrosine kinase
- clinical trial
- study protocol
- systematic review
- randomized controlled trial
- cerebrospinal fluid
- artificial intelligence
- data analysis
- deep learning
- brain metastases
- chronic myeloid leukemia